Literature DB >> 6170683

Regulation of human natural killing. I. The role of monocytes, interferon, and prostaglandins.

H S Koren, S J Anderson, D G Fischer, C S Copeland, P J Jensen.   

Abstract

We have found that human endogenous natural killer activity as measured in a rapid 51Cr release assay is unaffected by the presence of monocytes. Moreover, stimulation of natural killer cells by poly I:C is independent of monocytes. In contrast, the presence of monocytes in a mixed population of mononuclear cells that have been stimulated by poly I:C suppresses NK activity. The suppression is shown to be partially reversible if indomethacin (10(-6) M) is added to the cultures during stimulation. Culture supernatants of monocytes stimulated with poly I:C are shown to contain PGE1 in a radioimmunoassay, and have NK inhibitory activity comparable to that obtained with exogenous PGE1 added to NK assays at a concentration range of 10(-7) to 10(-9) M. Culture supernatants from poly I:C-stimulated monocytes do not have detectable levels of antiviral activity. In contrast, plastic nonadherent cells stimulated with poly I:C produce significant levels of interferon (100 to 200 U/ml/2 x 10(6) cells) but almost undetectable amounts of PGE. Supernatants of nonadherent cells incubated with indomethacin (10(-6) M) alone augment NK activity. Taken together, the results suggest that stimulation of mononuclear cells with poly I:C is dependent on and regulated by the relative levels of interferon produced by lymphocytes and PGE produced by monocytes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6170683

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Identification of an evolutionarily conserved, function-associated molecule on human natural killer cells.

Authors:  D T Harris; L Jaso-Friedmann; R B Devlin; H S Koren; D L Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  Natural killer cell function is not diminished in the healthy aged and is proportional to the number of NK cells in the peripheral blood.

Authors:  G J Ligthart; H R Schuit; W Hijmans
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

3.  Human macrophage activation. Modulation of mannosyl, fucosyl receptor activity in vitro by lymphokines, gamma and alpha interferons, and dexamethasone.

Authors:  T Mokoena; S Gordon
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 4.  Regulation of natural killer activity.

Authors:  J R Ortaldo
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Human mononuclear phagocytes from different anatomical sites differ in their capacity to metabolize arachidonic acid.

Authors:  E Vicenzi; A Biondi; C Bordignon; A Rambaldi; M B Donati; A Mantovani
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

7.  Investigation of porcine natural-killer cell activity with reference to African swine-fever virus infection.

Authors:  S G Norley; R C Wardley
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

Review 8.  Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

9.  Role of lipoxygenase products in murine pulmonary granuloma formation.

Authors:  S L Kunkel; S W Chensue; C Mouton; G I Higashi
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

10.  Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum.

Authors:  A A Gaspari; T A Fleisher; K H Kraemer
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.